The acquisition will be funded through long term debt and internal accruals. Razel ranks among the top 10 brands in India in the rosuvastatin molecule category, with the combined sales of Rs 66.1 crore as of year end October 2022 as per IQVIA data.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fh7nwco
via IFTTT
0 comments:
Post a Comment